[go: up one dir, main page]

ZA200004925B - Benzoates derivatives for inhibiting angiogenesis. - Google Patents

Benzoates derivatives for inhibiting angiogenesis. Download PDF

Info

Publication number
ZA200004925B
ZA200004925B ZA200004925A ZA200004925A ZA200004925B ZA 200004925 B ZA200004925 B ZA 200004925B ZA 200004925 A ZA200004925 A ZA 200004925A ZA 200004925 A ZA200004925 A ZA 200004925A ZA 200004925 B ZA200004925 B ZA 200004925B
Authority
ZA
South Africa
Prior art keywords
group
alkyl
aryl
alkoxy
halogen
Prior art date
Application number
ZA200004925A
Other languages
English (en)
Inventor
Daniel Tuse
Charles Hiebert
Keith R Laderoute
Nahid Waleh
Original Assignee
Biosource Tech Inc
Stanford Res Inst Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosource Tech Inc, Stanford Res Inst Int filed Critical Biosource Tech Inc
Publication of ZA200004925B publication Critical patent/ZA200004925B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200004925A 1998-03-25 2000-09-15 Benzoates derivatives for inhibiting angiogenesis. ZA200004925B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7931398P 1998-03-25 1998-03-25

Publications (1)

Publication Number Publication Date
ZA200004925B true ZA200004925B (en) 2001-11-28

Family

ID=22149749

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200004925A ZA200004925B (en) 1998-03-25 2000-09-15 Benzoates derivatives for inhibiting angiogenesis.

Country Status (9)

Country Link
US (1) US6150407A (fr)
EP (1) EP1063985A1 (fr)
JP (1) JP2002507567A (fr)
KR (1) KR20010042168A (fr)
AU (1) AU3109199A (fr)
CA (1) CA2324347A1 (fr)
IL (1) IL138572A0 (fr)
WO (1) WO1999048495A1 (fr)
ZA (1) ZA200004925B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058469A1 (fr) * 2000-02-08 2001-08-16 Wax Martin B Methodes de traitement du glaucome
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
AUPR500201A0 (en) 2001-05-14 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Recovery of minerals by flotation
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
ATE428419T1 (de) * 2001-08-06 2009-05-15 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
ES2369534T3 (es) 2002-06-06 2011-12-01 Canbas Co. Ltd. Compuestos que anulan el punto de control g2 del ciclo celular inducido por daños en el adn y/o que incrementan la actividad anticancerosa de los tratamientos que dañan el adn.
WO2005105133A2 (fr) * 2004-04-23 2005-11-10 Massachusetts Eye And Ear Infirmary Methodes et compositions de conservation de la viabilite de cellules photoreceptrices
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
WO2008063639A2 (fr) 2006-11-21 2008-05-29 Massachusetts Eye And Ear Infirmary Compositions et procédés pour préserver des cellules de l'oeil
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
JP5791064B2 (ja) * 2009-07-17 2015-10-07 エア・ウォーター株式会社 医薬用組成物
WO2012079088A2 (fr) 2010-12-10 2012-06-14 The Johns Hopkins University Peptides mimétiques dérivés de collagène de type iv et leur utilisation pour traiter des maladies dépendantes de l'angiogenèse et de la lymphangiogenèse
TWI458477B (zh) * 2011-08-11 2014-11-01 Univ Chia Nan Pharm & Sciency 用以抑制乳癌細胞生長之雙苯基醚化合物及其製造方法
US20130101663A1 (en) * 2011-10-19 2013-04-25 Henry John Smith Soluble tumor necrosis factor receptor (sTNF-R) used as a targeting agent to treat arthritis and other diseases
US20130115269A1 (en) * 2011-11-04 2013-05-09 Henry John Smith Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
CA2905509A1 (fr) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Imagerie cardiaque a ciblage hsp90 et traitement associe
WO2017031157A1 (fr) 2015-08-18 2017-02-23 Mateon Therapeutics, Inc. Utilisation de vda pour améliorer des thérapies d'immunomodulation contre des tumeurs
WO2017197045A1 (fr) 2016-05-11 2017-11-16 Movassaghi Mohammad Synthèse totale convergente et énantiosélective d'analogues de la communesine
WO2018209239A1 (fr) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (fr) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
EP1063985A1 (fr) 2001-01-03
JP2002507567A (ja) 2002-03-12
AU3109199A (en) 1999-10-18
CA2324347A1 (fr) 1999-09-30
WO1999048495A1 (fr) 1999-09-30
KR20010042168A (ko) 2001-05-25
IL138572A0 (en) 2001-10-31
US6150407A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
US6150407A (en) Methods for inhibiting angiogenesis
US6433012B1 (en) Method for inhibiting inflammatory disease
US6169104B1 (en) Di-aryl ethers and their derivatives as anti-cancer agents
AU2002311985B2 (en) Methods for inhibiting angiogenesis
AU2002311985A1 (en) Methods for inhibiting angiogenesis
JP7001599B2 (ja) 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法
US7468355B2 (en) Methods for inhibiting cancer and scar formation
JP2005527487A (ja) 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
KR100468271B1 (ko) 피페라진옥시란유도체를포함하는약제학적조성물
US20040048808A1 (en) Methods for inhibiting angiogenesis
EP0768084A1 (fr) Inhibiteur de la metastase cancereuse
MXPA00009345A (en) Benzoates derivatives for inhibiting angiogenesis
US20240207301A1 (en) Pharmaceutical composition and anti-tumor agent for tumor having decreased function of at least one of bap1 or pbrm1
MXPA99008753A (en) Di-aryl ethers and their derivatives as anti-cancer agents
NZ540607A (en) Methods for inhibiting cancer and scar formation
EP0981337A2 (fr) Activite anti-angiogenique amelioree des derives constamment charges d'hormones steroidiennes